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Summary 
Rheumatoid Arthritis (RA) is the commonest inflammatory polyarthritis in the UK, and is 
associated with significant symptoms, disability and premature mortality. Treatment 
options in 1980 were restricted to corticosteroids, non-steroidal anti-inflammatory drugs, 
and a small number of disease modifying anti-rheumatic drugs (DMARDs). There had 
been few large, well conducted randomised controlled studies such that our knowledge 
about the relative efficacy and safety of the drugs available was very limited. Trial design 
also left much to be desired, with inadequate methods of randomisation and/or 
concealment of allocation being commonplace. There was no consensus about which 
outcome measures ought to included in trials, and no composite measures of outcome had 
yet been developed or validated. The limited evidence base and restricted therapeutic 
armamentarium was reflected in the poor outcome of the disease for many patients: 
remission was rare, and patients often experienced increasing disability, orthopaedic 
intervention, work-related unemployment and premature mortality.  
 
Within 20 years, the prognosis for patients with newly diagnosed RA has dramatically 
improved. Modern management results in the majority of patients achieving low disease 
activity or even remission. The studies incorporated into this thesis have played an 
important role in the evolution of these management strategies. Early studies focussed on 
building the evidence base for the use of DMARD monotherapy, demonstrating that 
sulfasalazine and methotrexate were both safe and effective treatments. The Sulfasalazine-
Auranofin trial contributed to the downfall of auranofin, a drug that is no longer 
manufactured. Contrary to early concerns, methotrexate was proven to be well tolerated, 
even in the socially deprived population of Greater Glasgow, and this drug had become the 
DMARD of first choice in the management of RA. DMARD monotherapy, however, is 
usually not sufficient to maintain good disease control in the long term. The Gold-
Hydroxychloroquine study was one of the first studies to investigate the role of 
combination DMARD therapy in a well conducted, double blind randomised controlled 
trial (RCT). The results were negative, but a follow up trial demonstrated the superiority of 
stepping up to Methotrexate-Sulfasalazine combination therapy when compared to 
sequential monotherapy in the MASCOT study. The West of Scotland Early RA 
corticosteroid trial was a double blind RCT investigating the role of low dose oral 
corticosteroids in addition to sulfasalazine therapy. It failed to demonstrate any benefit of 
low dose steroids, a finding that is at odds with a growing literature that has established 
corticosteroids as a proven disease modifying therapy. 
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The strategy trials (Tight Control of RA [TICORA] and Triple Therapy in Early RA 
[TEAR] studies) have been the most influential studies to have been performed in 
Glasgow. They did not primarily address the issue of whether a drug is effective or 
whether one drug is more effective than another. Rather, they sought to test a hypothesis 
drawn from observations in other biologic models (principally Type I Diabetes Mellitus): 
namely, that i) using currently available DMARDs ‘tight control’ can be achieved if 
patients are reviewed frequently, their disease assessed formally (using the disease activity 
score), and their treatment escalated if their disease remained active; ii) that the 
achievement of tight control would lead to improved outcomes. The studies provided 
strong evidence that dramatic improvements in symptom control, disability and 
radiographic progression can be achieved by pursuing this strategy of ‘Tight Control’. 
National and international clinical guidelines, and international consensus statements have 
embraced the results of TICORA (and subsequent confirmatory studies), such that regular, 
frequent assessment of the patient, use of composite measures of disease activity and the 
adoption of a ‘treat-to-target’ therapeutic strategy have become accepted as ‘best practice’ 
throughout the world. 
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Chapter 1 - Introduction 
Epidemiology 
Rheumatoid arthritis is the commonest inflammatory polyarthropathy in the UK, affecting 
810/100,000 of the population. The annual incidence of newly diagnosed RA is 25/100,000 
men and 54/100,000 women, with a peak incidence in the 5th and 6th decades of life (Wiles 
et al. 1999). Typically, RA causes a symmetrical, inflammatory polyarthropathy affecting 
large and small joints which results in pain, stiffness, fatigue and loss of function. 
Persistent inflammation results in joint damage, such that ~20% of patients require 
orthopaedic intervention (such as joint replacement) over a 20 year period (Scott et al. 
1987). Mortality, in patients with established disease, is increased when compared to the 
general population (Myasoedova et al. 2010). The cost of illness was estimated at £ 1.3 
billion pa in England in 1992, comprising both direct NHS costs and societal costs 
(McIntosh 1996). 
Pathogenesis 
Our knowledge about the aetio-pathogenesis of RA has expanded significantly over the 
past twenty years, but the specific cause(s) remain elusive. The heritability of RA has been 
estimated at 67% indicating a strong genetic component to the aetiology of RA (van der 
Woude et al. 2009). Genome-wide association scans have identified a number of genetic 
pre-dispositions to the development of RA (table 1). The strongest association is with the 
‘shared epitope’ (e.g. HLA DR4) which implicates antigen presentation by T-cells to 
macrophages in the pathogenesis of the disease. Many of the other genetic pre-dispositions 
identified also code for proteins involved in the immune response (e.g. PTPN22) which is 
highly suggestive that these genes give rise to an increased risk of disease because of 
dysregulation of the immune response (Bax et al. 2011, Daha et al. 2009, Padyukov L. 
Seielstad M. Ong RT. Ding B. Ronnelid J. Seddighzadeh M. Alfredsson L. Klareskog L. 
Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study group 2011). 
Table 1 – susceptibility genes for RA (Bax et al. 2011) 
Genes  Year of Discovery 
HLA-DRw4 1978-1987 
PAD14, PTPN22, CTLA4 2003-2005 
TRAF1/C5, STAT4, TNFAIP3 2007 
KIF5A, PIP4K2C, TNFRSF14, CCL21, PRKCQ, CD40, 
1L2RA, 1L2RB 
2008 
PRDM1, CD2, CD58, FCGR2A, PTPRC, REL, BLK 2009 
ANKRD55, IL6ST, C5orf13, GIN1, SPRED2, CCR6, AFF3, 
IRF5, PXK, RBPJ 
2010 
TAGAP, DDX6 2011 
  7 
Studies over the past twenty years have also identified important environmental factors that 
contribute to the development of RA. Probably the strongest of these is the association 
with cigarette smoking, but associations with social deprivation and periodontal disease 
(Hitchon et al. 2010) have also been identified. It is of particular interest that the 
interaction between environmental and genetic factors have been shown to be of 
importance. This has been shown most elegantly in studies of patients who develop RA in 
whom samples had been stored because they had previously been blood donors: the 
presence of anti-citrullinated protein antibodies (ACPA), shared epitope, certain PTPN22 
alleles and smoking interact, leading to substantial variations in the risk of developing RA 
(Willemze et al. 2011). 
Taken together, these findings have led to the current thinking on the likely aetio-
pathogenesis of RA: a genetic pre-disposition is present in some subjects (e.g. shared 
epitope), who may then be exposed to an environmental trigger (such as cigarette 
smoking); a proportion of these patients respond by producing auto-antibodies such as 
ACPA. At this stage, there is therefore evidence of B cell immune dysregulation, but no 
clinical sequelae – and this is often referred to as the ‘pre-RA’ phase of disease. Over time, 
a proportion of subjects develop a non-specific prodrome of arthralgia and  stiffness, which 
may lead them to seek help from a rheumatologist. It may be impossible for the clinician to 
make a specific diagnosis at this stage, because of the lack of overt synovitis (clinical or 
radiological) but over two years, approximately 40% of patients go on to develop overt 
inflammatory arthritis that fulfils the American College of Rheumatology Classification 
Criteria for RA (Bos et al. 2010). 
Treatment 
Until the mid 1980’s, treatment of RA was conservative, and initially followed clinician 
specific (idiosyncratic) approaches from which emerged the paradigm of a treatment 
‘pyramid’ – at presentation, patients were treated with analgesia and/or non-steroidal anti-
inflammatory drugs (NSAIDs). If the patient’s symptoms were not controlled, or erosive 
disease developed, then conventional disease-modifying antirheumatic drugs (DMARD) 
were introduced. Corticosteroid or immunosuppressive therapy (at the top of the pyramid) 
was reserved for that sub-group of patients with the most severe disease who failed to 
respond to other therapy. The rationale for this approach was partly a reaction against the 
false dawn of the discovery of corticosteroids, and their indiscriminate use at high doses, in 
which initial dramatic improvements were followed by loss of response and catastrophic, 
delayed steroid toxicity. Consequently, the principle, ‘first do no harm’ (primo non nocere) 
came to dominate therapeutic decisions – it was recognised firstly that DMARDs could be 
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associated with serious drug-related toxicity, and secondly that the evidence base 
supporting their efficacy was limited.  
Improved outcome 
In the 1980s, the outcome of DMARD therapy remained relatively poor. An editorial 
published in 1993, entitled ‘Gold – standard, sham or substitute?’ summed up the 
prevailing doubts about the risk-benefit profile of the available therapies (Harth 1993). A 
majority of patients who were commenced on any of the available conventional DMARDs 
stopped as a result of inefficacy and/or toxicity. The usual pattern was one of slow 
functional decline over a number of years, with increased mortality (Scott et al. 1987). 
Even as late as 2000, the Scottish Inter-Collegiate Guideline Network concluded that 
remission in RA is uncommon. However, a decade later there is a new optimism about the 
therapy and outcome of RA. The DREAM cohort recently reported that after two years of 
disease, modern management leads to >60% of patients to be in stable disease remission 
(Vermeer et al. 2011). What has led to this dramatic improvement in outcome? National 
and European clinical guidelines on the management of RA have been published and 
highlight the following developments (Smolen et al. 2010, Smolen et al. 2010): 
Early intervention 
It has become apparent that not only is the risk-benefit ratio in favour of the use of 
conventional DMARDs but that delays in the use of DMARD therapy can be associated 
with long term harm. Consequently, it is recommended that treatment with DMARDs is 
started as soon as possible in the disease course, preferably within 12 weeks of symptom 
onset (van der Linden et al. 2010). 
Combination DMARD therapy 
In the 1980s there was vigorous debate about the safety of DMARDs used singly, and 
suggestions that two or more DMARDs should be used in combination didn’t emerge until 
the 1990’s. Even then, the evidence for the efficacy of combination DMARD therapy was 
initially conflicting. Better trial design and high quality studies have subsequently proven 
that some DMARD combinations offer superior efficacy when compared to single 
DMARDs (Choy et al. 2005, Donahue et al. 2008, Nam et al. 2010). 
Biologic therapy 
The emergence of targeted biologic therapies has revolutionised the management of RA. 
The ability to design a treatment that targets a specific protein, pathway or cell type 
involved in the pathological immune response in RA, has led to a range of novel biological 
therapies. These therapies have been proven to be effective even in patients who have 
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failed to respond to multiple conventional DMARDs. Concerns about serious toxicity are 
slowly abating through the compilation of large national safety databases and registries. 
Tight control of RA 
Both national and European guidelines now recommend a ‘treat-to-target’ management 
strategy, whereby patients are assessed frequently, have their disease activity assessed 
formally (usually using a composite Disease Activity Score), and treatment adjusted where 
persistent disease activity is identified (Smolen et al. 2010). The background to these 
recommendations will be discussed later in this thesis, but suffice to say that the advent of 
new strategies of care has been at least as important in improving outcomes as the 
expanding arsenal of new drugs: 
 
“… the most important information to be gathered from clinical trials in RA is not 
necessarily comparison of agents, but rather the strategy of tight control, aiming 
for remission.” (Sokka, Pincus 2009) 
Objective 
The objective of this thesis is to review the contribution of randomised controlled trials 
designed (and largely conducted in) a single centre in Glasgow between 1991 and 2011 
(table 2). The author has been involved in the design, execution, analysis or reporting of all 
the trials discussed. The study will particularly address 1) the contribution of each trial to 
the emerging evidence base, and 2) the evolution of study design, with special reference to 
the quality of the studies performed. 
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Table 2 - Summary of clinical trials performed 
Comparators Study 
Design 
Concealment Duration Year of 
Publication  
Role* 
Sulfasalazine vs 
auranofin (SSZ/Aur) 
RCT Open 12 
months 
1992 A, P 
Gold vs Gold + 
hydroxychloroquine 
(Gold/HCQ) 
RCT Double blind 12 
months 
1993 A, P 
Gold vs 
methotrexate 
(Gold/MTX) 
RCT Open 12 
months 
2001 D, C, P 
Prednisolone vs 
placebo 
(WOSERACT) 
RCT Double blind 12 
months 
2004 D, C, A, P 
Methotrexate and 
Sulfasalazine 
Combination Trial 
(MASCOT) 
RCT Double Blind 12 
months 
2007 D, C, A, P 
Routine vs intensive 
management 
(TICORA) 
RCT and 
economic 
evaluation 
Blinded 
assessments 
18 
months 
2004 D, C, A, P 
Triple therapy vs 
Step-up therapy 
(TEAR) 
RCT, 
strategy 
Blinded 
assessments 
12 
months 
2008 D, C, A, P 
* Role – Study design (D), conduct (C), analysis (A), publication (P) 
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Chapter 3 – Quality of Clinical Trials 
Clinical trials in Glasgow have contributed significantly to our knowledge about how to 
manage patients with newly diagnosed and established RA. The design of these RCTs has 
evolved over the years, and issues such as randomisation, choice of outcome measures and 
the role of strategy trials will be discussed. The quality of clinical trials is of obvious 
importance if clinicians are to have confidence in their results, and there is a substantial 
literature that has emerged surrounding the assessment of quality: 
Assessment of bias 
The Cochrane Handbook defines bias as “a systematic error, or deviation from the 
truth, in results or inferences” which can “operate in either direction: different biases 
can lead to underestimation or overestimation of the true intervention effect. Biases can 
vary in magnitude: some are small (and trivial compared with the observed effect) and 
some are substantial (so that an apparent finding may be entirely due to bias)” 
(Higgins, Green 2011).  
 
The risk of bias in a study is related to its’ quality – low quality trials introduce a 
higher risk of bias – but the two dimensions are not identical. For instance, some issues 
of quality (such as obtaining ethical approval) do not relate to the risk of bias. Some 
trial designs also introduce a risk of bias, but should not be characterised as being of 
poor quality, because of impossibility or impracticality – for example, open studies 
introduce a risk of bias, but it may be impractical to design a double blind study. 
 
Some studies have shown that trial quality, as assessed by the Jadad score (Jadad et al. 
1996, Jadad et al. 1996), has an impact on the likelihood of reporting a positive 
outcome – open (unblinded) studies, those that report inadequate concealment of 
allocation, and those with a Jadad score <2 were associated with an increased estimate 
of benefit (Schulz et al. 1995b, Moher et al. 1998). This conclusion is not universal: for 
example, Emerson et al found no association between quality and the likelihood or 
magnitude of treatment differences (Emerson et al. 1990). 
Assessing quality of Randomised Controlled Trials 
Assessing the quality of randomised controlled trials is challenging. Moher et al 
reviewed 25 published scales and 9 checklists, and noted considerable heterogeneity in 
these, and obvious shortcomings in most (Moher et al. 1995). The evidence concerning 
the question of whether the use of different scales alters the assessment of quality is 
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mixed, but in some circumstances applying a different scale is associated with changes 
in the assessment of quality (Detsky et al. 1992, Moher, Jadad & Tugwell 1996). The 
uncertainty surrounding the usefulness of using scales and checklists have led the 
Cochrane Collaboration to recommend that these are not used, in favour of a 
descriptive tool. Indeed, the use of the Jadad score is explicitly discouraged partly 
because concealment of allocation (one of the few factors consistently associated with 
an increased estimate of benefit if it is lacking) is not included in the scale (Higgins, 
Green 2011). Nonetheless, the Jadad score remains the most widely used scale in 
methodological reviews of study quality (Dechartres et al. 2011), and so the Glasgow 
studies’ Jadad score is shown in Appendix 1. In place of the Jadad score, the Cochrane 
Collaboration recommends the descriptive assessment of the following domains: 
a. Random sequence generation 
b. Allocation concealment 
c. Blinding of participants and personnel 
d. Blinding of outcome assessment 
e. Completeness of outcome data 
f. Evidence of selective reporting 
g. Other sources of bias 
These domains have formed the basis of the ‘Assessment of Risk of Bias’ table for 
each study (Appendix 2). 
Randomisation and Concealment of Allocation 
The methods used for allocation of participants to their therapy in the various studies 
are summarised in Table 3.  
Table 3 – Method of randomisation and allocation concealment 
Trial  Allocation Method of randomisation and concealment 
SSZ/Aur Partial randomisation Sealed envelopes 
Gold/HCQ Random Not stated 
Gold/MTX Random Sequential allocation to therapies determined by 
random number tables, which were not 
concealed. 
WOSERACT Random In pharmacy 
MASCOT  Random In pharmacy 
TICORA Random Telephone to study co-ordinator using 
randomisation software  
TEAR Random Telephone to study co-ordinator using 
randomisation software 
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Over 20 years, there has been an improvement in the study design, partly explained by the 
advances in information technology. The earliest studies used two different methods of 
randomisation. In the SSZ/Aur study, an equal number of cards marked with each drug 
name were placed into opaque envelopes which were then shuffled and numbered. 
Sequential patients recruited to the study were then allocated their therapy according to the 
drug in the next envelope. However, a significant proportion of the patients were allocated 
their treatment because they had already received the comparator drug. Study records are 
no longer extant, and it is not clear how this was handled by the ‘randomisation’ process – 
possibly, if the opened envelope indicated the ‘wrong’ drug that allocation was held over 
for the next patient. What is clear is that 1) the process fell substantially short of full 
randomisation 2) the methodology was poor and 3) the fact that not all the patients’ 
therapy was randomised is clear from the study report. 
In the Gold/MTX study, a different but also sub-optimal methodology was used. In this 
study, random number tables were used to generate a random order of drug allocation. This 
order was recorded in a master study file; when a patient was recruited to the study, the 
next study number (and its allocated treatment) was assigned to the patient. However, the 
master study file was not concealed such that potentially 1) the next treatment to be 
allocated could be ascertained in advance 2) if two patients needed to be allocated at the 
same time, the next two treatment could be allocated to the patients (rather than 
randomised). It is not known if the lack of concealment led to any flaws in the 
randomisation process, but it certainly raises the possibility of potential bias. Importantly, 
this flaw in study design is not discernible from the published report. 
The double blind studies (WOSERACT, Gold/HCQ, MASCOT) all had full randomisation 
and concealment which can confidently be assumed to have eliminated allocation bias, The 
most recent studies have been open label, with blinded assessments of outcome (TICORA, 
TEAR) but have all used off-site randomisation, either by a trial co-ordinator using 
randomisation software. Again, a lack of allocation bias can be confidently relied upon. 
In summary, there has been an evolution in study methodology over twenty years, with a 
definite improvement leading to increased confidence in the elimination of allocation bias. 
Outcome Measures 
The outcome measures employed in RA clinical trials has evolved significantly over the 
last twenty years: 
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1. The individual variables employed to assess disease activity and outcome has changed 
such that some are now rarely employed, if ever (e.g. the measurement of grip strength) 
whereas others have become much more widely used (e.g. generic measures of health-
related quality of life such as SF36). 
2. International consensus has been sought through the auspices of the Outcome Measures 
in RA Clinical Trials (OMERACT) initiative leading to recommendations about which 
outcome measures should be utilised in all clinical trials (Felson et al. 1993). 
3. The use of composite outcome measures has been the most significant development 
(Table 4). The process has taken twin tracks on either side of the Atlantic. In the USA, 
the American College of Rheumatology developed the ACR20% response criteria, 
which was specifically designed to maximise the statistical power in discriminating 
between active drugs and placebo in RCTs. Later iterations of the process have led to 
the development of the nACR response criteria, and the hybrid ACR response criteria 
(Felson, American College of Rheumatology Committee to Reevaluate Improvement 
Criteria 2007). The latter add further ability to distinguish active response from placebo 
response, but have not yet been widely employed as primary outcome measures in 
clinical trials. 
 
In Europe, the disease activity score (DAS) (van Gestel et al. 1996) was subsequently 
developed, and followed by several alternatives including the DAS28 (Prevoo et al. 
1995) (based on a smaller number of joints being assessed), clinical disease activity 
index (CDAI, which does require any laboratory results to score), and the simplified 
disease activity index (SDAI) (Smolen et al. 2003). DAS can also be used to categorise 
patients according to EULAR response by defining remission, good response, moderate 
response, or no response.  
Table 4 – Composite outcome measures 
Outcome measure Abbreviation Components 
ACR Response Criteria  ACR20/50/70, 
nACR, ACR Hybrid 
SJC, TJC, ESR/CRP, PS, 
PGA, AGA, HAQ 
Disease Activity Score  DAS SJC, RAI, ESR, PGA 
28 joint count Disease Activity 
Score  
DAS28 SJC, TJC, ESR, PGA 
Simplified Disease Activity Index SDAI SJC. TJC, PGA, AGA, CRP 
Clinical Disease Activity Index CDAI SJC. TJC, PGA, AGA 
SJC – Swollen Joint Count; TJC – tender joint count; PS – visual analogue pain score; PGA – patient global 
assessment of disease activity; AGA – assessor global assessment of disease activity; HAQ – health 
assessment questionnaire; RAI – Ritchie articular index 
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It is now almost inconceivable that a RCT between two DMARDs or DMARD strategies 
would not use one of these composite measures as an outcome measure. In Glasgow, the 
outcome measures used are shown below: 
Table 4 – Outcome Measures used 
Trial  Primary Outcome  Secondary outcome measures 
SSZ/Aur - Ritchie AI, VAS pain score, duration of 
morning stiffness, ESR, CRP, platelet count 
Gold/HCQ - Ritchie AI, VAS pain score, duration of 
morning stiffness, grip strength, ESR, CRP, 
Global wellbeing (Likert scale, 1-5), Health 
Assessment Questionnaire. 
Gold/MTX - Ritchie AI, VAS pain score, duration of 
morning stiffness, ESR, CRP, Global 
wellbeing (Likert scale, 1-5), Health 
Assessment Questionnaire, modified Paulus 
response and Menninger response. 
WOSERACT Total Sharp Score Ritchie AI, VAS pain score, ESR, CRP, 
Physician Global assessment (Likert scale, 
1-5), Patient Global assessment (Likert 
scale, 1-5), Health Assessment 
Questionnaire 
MASCOT  DAS EULAR good response, remission, 
ACR20/50/70, HAQ 
TICORA DAS EULAR good response, remission, 
ACR20/50/70, HAQ score, SF36, Total 
Sharp Score, Economic evaluation 
TEAR DAS28 EULAR good response, remission, 
ACR20/50/70, HAQ score, SF12, Total 
Sharp Score 
 
The use of composite outcome measures has become the norm in clinical trials, but there 
has been an interesting development that has grown out of this, namely, that their use has 
become increasingly widespread in routine clinical practice. This has been in no small part 
due to the positive findings in the TICORA study whereby the routine and systematic use 
of DAS to guide therapeutic decisions (within the context of a tight control strategy) led to 
far better clinical outcomes. Consequently, national and international guidelines 
recommend the use of composite outcome measures in routine clinical practice (National 
Institute for Health and Clinical Excellence 2009). 
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Chapter 4 –Scientific Contribution of studies 
Only a small number of DMARDs were in routine use in the management of RA in the 
1980’s. Rational prescribing decisions were limited by a lack of high quality evidence from 
randomised controlled trials. Those studies that had been performed tended to be small 
without validated outcome measures, which limited their usefulness.   
! Intramuscular gold had been shown to have disease modifying properties in 1960 
(Anonymous1960) but inefficacy and serious toxicity were common such that only 
a small proportion of patients remained on therapy for longer than 5 years (Sinclair, 
Duthie 1949) (Maetzel et al. 2000). 
! Sulfasalazine (SSZ) had originally been developed in the 1930’s but  was not re-
discovered until the early 1980’s when two studies rekindled interest in the drug for 
the treatment of RA (Pullar, Hunter & Capell 1983, McConkey et al. 1980); even 
then, the evidence remained relatively weak, for instance, with no direct evidence 
that SSZ therapy was associated with reduced radiographic progression.  
! Penicillamine was also used widely as a DMARD, as the result of a double blind 
placebo controlled trial reported in 1973. This demonstrated improvements in 
clinical symptoms (such as pain), acute phase response (ESR) and function (grip 
strength). Once again, modification of radiographic progression was not 
demonstrated, and significant toxicity was recorded (Golding et al. 1973)(Bunch et 
al. 1984a) 
! Chloroquine and hydroxychloroquine were widely used in the management of RA 
(Clark et al. 1993, Freedman 1956). At the time, anti-malarials were believed to be 
less efficacious, but safer, than the other DMARDs available, an impression that 
has subsequently been confirmed in RCTs (van der Heijde et al. 1990). 
! Methotrexate was just becoming available in the mid 1980’s with placebo 
controlled RCTs demonstrating superiority over placebo (Williams et al. 1985). 
Initial concerns about the potential for hepatotoxicity led to caution in its 
widespread use, particularly in Europe, but over time its safety record, tolerability 
and efficacy have resulted in it becoming the most widely prescribed DMARD 
(Criswell, Henke 1995). 
The challenge facing the rheumatology community was to establish which DMARDs were 
effective, to evaluate their relative efficacy, and to identify drug combinations and/or 
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strategies that would optimise patient outcomes. The studies performed in Glasgow over 
two decades have contributed to the pursuit of these goals: 
Sulfasalazine and auranofin 
SSZ was first developed and used in the treatment of inflammatory arthritides by Nana 
Svartz in Sweden in the 1930’s. At the time, there was a belief that RA may have an 
infective aetiology and her rationale was to combine an anti-inflammatory agent (5-
aminosalicylic acid) with an antibiotic (sulfapyridine). The original reports were 
encouraging; the patients included had a number of diagnoses, which with hindsight did 
not necessarily negate her results (Svartz 1948). Nevertheless, interest in the drug 
diminished when a negative report of a study in RA was published in the UK (Sinclair, 
Duthie 1949). Interest in the use of SSZ was not re-kindled until the 1980s when two 
positive trials were reported (Pullar, Hunter & Capell 1983, McConkey et al. 1980). 
Auranofin (Aur), a water soluble gold salt, was developed as an oral alternative to the 
injectable gold salts that had been in use since the 1950s. Placebo controlled RCTs have 
demonstrated the superiority of Aur over placebo with improvements in clinical and 
laboratory markers of disease activity (Johnsen et al. 1989, Ward et al. 1983, Williams et 
al. 1984)(Menard et al. 1982, Schattenkirchner et al. 1982, Smith, Brown & Meyers 1982). 
Interestingly, considering that it has subsequently fallen out of favour because of a poor 
risk-benefit profile, Aur was one of the few drugs in the 1980s to be proven to slow 
radiographic progression in RA (Katz et al. 1982). Small comparative RCTs suggested that 
Aur was probably better tolerated than injectable gold, but was somewhat less efficacious 
(Menard et al. 1982, Schattenkirchner et al. 1982, Smith, Brown & Meyers 1982). 
At the time the Glasgow trial was performed, very few head to head comparisons between 
two DMARDs had been published. It was important for rheumatologists and their patients 
to elucidate if one DMARD was preferable over another, to maximise the likelihood of 
clinical response and minimise the risk of toxicity. The study was designed to answer the 
question of whether SSZ or Aur had a better risk-benefit profile. The choice of an active 
comparator study, rather than a placebo controlled trial, is important. Placebo controlled 
trials had already shown superiority of both agents when compared to placebo, and it was 
deemed inappropriate to expose patients to a prolonged period without active  treatment 
through the inclusion of a placebo arm in the study. There are several significant 
limitations and weaknesses in the study design and reporting, which are an indication of 
how many improvements have been made over the past 20 years in this regard: 
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• ethical approval – the study had ethical approval but there is no mention of this in 
the study report 
• exactly 200 patients were recruited, and this is an indication that there were no 
power calculations performed, and that the sample size was arbitrary 
• randomisation – that the study was not truly randomised has already been discussed 
above (p14) 
• no primary outcome measure was selected 
Patients dropped out from their assigned therapy over the course of the trial such that 
63/50% of patients continued on SSZ/Aur respectively by the end of the trial. This design, 
whereby only patients who continued on their assigned therapy are analysed for efficacy, 
militates against a positive result – patients with a sub-optimal response could have their 
treatment changed to an alternative, thereby leaving the trial. Essentially, responding (at 
least partially) to therapy becomes a pre-requisite for staying on the trial, and hence for 
being included in the analysis. Consequently, it is unsurprising, if only responders are 
analysed, that differences between groups disappears with time. 
Analysis of disease activity at 12 weeks demonstrated that patients assigned to SSZ had 
significantly lower median ESR (28 vs 36, p=0.04 Mann-Whitney) and articular index (8 
vs 12, p=0.04 Mann-Whitney), but there were no significant differences in median CRP, 
duration of early morning stiffness or visual analogue pain score. There was a larger mean 
improvement with SSZ therapy in ESR (figures not provided, p=0.04, Students t-test) and 
CRP (p=0.026, Students t-test) between 0 and 12 weeks, but not between 0 and 24 or 0 and 
48 weeks. Various possible interpretations can be placed on these findings: 
1) SSZ is a more effective DMARD than Aur – the findings are consistent with this 
interpretation. However, the lack of positive findings in all measures of disease 
activity, or at subsequent time points needs to be explained. The convergence of the 
groups at 24, 36 and 48 weeks may be explained as above, namely, that the trial design 
(analyzing only ‘responders’) militates against finding a difference between the groups 
as follow up gets longer. In some regards, it is no surprise that comparisons between 
groups showed no significant differences between groups for individual variables. The 
magnitude of change expected with DMARD therapy in individual variables is small, 
compared with the variance of these variables; whilst these variables continue to be 
included in the EULAR ‘core set’ of outcome variables (Felson et al. 1993) it has been 
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amply demonstrated that composite outcome measures are much more sensitive at 
identifying differences in efficacy between different treatments. 
2) SSZ works faster than Aur – the findings are also consistent with the possibility that 
whilst SSZ works faster, it is ultimately no better than Aur. The data show that after 48 
weeks the patients remaining on therapy were as well controlled as those remaining on 
SSZ, indicating that in many patients (50% Aur vs 63% SSZ) Aur proved to be as 
effective a DMARD as SSZ. The difference in the number of patients remaining on 
therapy after 48 weeks were not statistically different, and the numerical difference 
between the groups can be largely explained by a very high drop out rate from the Aur 
group in patients who had previously received intramuscular gold (19/26 patients). 
3) SSZ and Aur are equally effective DMARDs – the statistical superiority of the SSZ 
group in a small number of variables after 12 weeks might be explained as follows: 
a. Multiple testing – the p values for the differences are only just less than 0.05, and in 
the absence of any adjustment for multiple comparisons might not be considered 
‘significant’. However, 3 out of 18 hypotheses tested were significant, and all 
favoured SSZ, which is more than would be expected by chance. 
b. Confounding – this is a significant concern with this trial:  >20% of patients were 
not randomized but had their therapy assigned because of their previous treatment. 
An attempt to mitigate this was made by performing a sub-group analysis, 
excluding patients who had been previously treated with intramuscular gold; this 
found that the superior benefit in the SSZ group after 12 weeks was still found, and 
was ‘statistically significant in more parameters’. However, ideally, this analysis 
would have excluded all patients who had not been randomised, thereby also 
excluding patients who had previously been treated with SSZ and who were 
assigned to the Aur group. 
c. Bias – the method and effectiveness of allocation concealment for those patients 
who were randomised is uncertain, which has been shown to be associated with 
larger estimates of treatment effects (Schulz et al. 1995a). 
In conclusion, whilst it is possible that the findings of this trial demonstrate that SSZ works 
significantly faster as a DMARD than Aur, the study design was associated with a 
significant risk of bias that would indicate that caution should be exercised in reaching 
definite conclusions. Over time, further evidence has accumulated that Aur is less well 
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tolerated that SSZ – after five years, a follow up reported that very few patients continued 
on Aur (McEntegart et al. 1996) – and the drug is no longer manufactured.  
Gold and hydroxychloroquine combination therapy 
In the early 1990’s the role of DMARD therapy was not yet fully established, although 
there was increasing evidence for the efficacy and safety of DMARD monotherapy. The 
role of combination DMARD therapy was even more uncertain, although there were its 
protagonists (Healey, Wilske 1991, Wilske, Healey 1989). In some parts of the world 
(Australia and Canada), combination therapy was quite commonly used and yet it was 
acknowledged that the evidence base was weak (Paulus 1990). Some uncontrolled, 
observational studies had been published, but few randomised controlled trials had been 
performed. A meta-analysis performed in 1994 concluded that combination therapy did not 
offer any substantial improvement in efficacy but was associated with higher toxicity 
(Felson, Anderson & Meenan 1994). However, the limitations of DMARD monotherapy 
were also acknowledged, particularly that relatively few patients responded well to 
therapy, and most patients continued to experience disease progression, leading to 
increasing joint damage and physical disability. The Gold/HCQ study was the first large, 
double blind placebo controlled studies to investigate the efficacy of adding a second 
DMARD (HCQ) to the treatment of patients with persistent disease activity despite the use 
of another (Gold). 
One of the strengths of this study was the careful characterisation of the study cohort. 
Concerns about the potential for increased toxicity associated with combination DMARD 
therapy, and the realisation that some patients responded well to DMARD monotherapy 
led to a study design that delineated a sub-group of patients who had made a sub-optimal 
response to IM gold therapy over a six-month period. This eliminated the risk of 
unnecessary use of combination therapy in patients who would respond well to a single 
drug. It is a study design that has prevailed, being employed in some modern trials of 
conventional and biologic DMARD management (van Vollenhoven et al. 2009). The study 
therefore recruited 440 patients with RA who were starting on IM gold therapy. Over the 
first 6 months, 25% responded well to IM gold and so did not need combination therapy. 
140 patients stopped their IM gold within 6 months, predominantly because of drug-related 
toxicity. A further 48 patients were not offered or declined the option of taking part in the 
trial, leaving 142 (32%) of the original cohort to be randomised. 
The analysis of the outcome measures suffered from the usual difficulties encountered 
commonly at that time, in that composite outcome measures had not been developed, 
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leading to very poor statistical power. Nonetheless, the lack of any improvement between 0 
and 6 months of combination therapy in most outcome measures argued against a large 
benefit from Gold/HCQ combination therapy. In retrospect, this finding may now be 
surprising – HCQ used in combination with MTX (+/- SSZ) has been proven to be more 
effective than MTX monotherapy, and has become the mainstay of many patients’ therapy 
(O'Dell et al. 1996, O'Dell et al. 2002). Of course, it is possible that there is drug specific 
synergism between MTX and HCQ that does not exist between HCQ and IM gold. The 
possibility, however, that the Gold/HCQ study gave a negative result as the result of a 
Type 2 error must also be borne in mind. 
The study emphasises the importance of a careful assessment of the value of different 
combinations of DMARDs. It should not be assumed that two DMARDs that are both 
effective as monotherapy will inevitably work together additively or synergistically. A 
recent example includes the observations that TNF inhibitors are more effective when co-
prescribed with methotrexate, but that adding methotrexate to tocilizumab appears to 
afford no additional benefit. 
Gold and methotrexate 
Methotrexate had emerged in the mid 1980s as a safe and effective DMARD. The 
popularity of MTX grew quickly in the USA whereas in Europe IM gold remained a 
mainstay of DMARD therapy, second only to SSZ in popularity. In many centres, 
including Glasgow, SSZ was the DMARD of first choice. In patients who failed to 
respond, or who developed drug-related toxicity, the question arose as to which drug to use 
next. There was concern in the West of Scotland, that methotrexate toxicity may be more 
common in the local population because of social derivation, poor nutrition, smoking and 
high alcohol intake. On the other hand, it was widely recognised that IM gold is poorly 
tolerated in the long term, and in the USA continuation rates with methotrexate were 
substantially higher (Maetzel et al. 2000). The Gold/MTX study set out to compare the 
efficacy and safety of IM gold and methotrexate in the West of Scotland in a prospective, 
open label, randomised controlled trial. 
There were significant limitations in the trial design:   
1) the method of allocation concealment was inadequate and could have introduced 
allocation bias. It is not possible to ascertain whether this occurred, or if it would have 
affected the results of the study (or in which direction, in favour of MTX or IM gold). 
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2) there were no power calculations performed to determine the sample size. It is 
important to consider whether the lack of any significant difference in clinical 
response, between groups, was the result of inadequate sample size leading to a Type 2 
error.  
3) dose of comparator drugs – in hindsight, the initial dose of methotrexate (5mg/wk) and 
rate of dose escalation (2.5mg/wk/month) was unnecessarily cautious. The caution was 
understandable, given that the rationale for the trial included a concern that the study 
population in the West of Scotland would be particularly susceptible to MTX toxicity. 
However, time has taught us that MTX can be started at a higher dose (7.5 – 15mg/wk) 
and escalated rapidly to 20 mg/wk within 4-8 weeks. In the study, it would have taken 
6 months to reach a dose of 20mg/wk; it is notable that the only statistically significant 
difference between the groups in any efficacy outcome variable at any time point was a 
lower ESR in the IM gold group after 12 weeks. Almost certainly, this resulted from 
the slower dose escalation rather than an intrinsically slower treatment response with 
MTX. The average dose of MTX at the end of the trial was also considerably lower 
(10mg/wk) than in other reports (Grigor et al. 2004), which might have limited the 
clinical response. 
Despite these limitations, the study yielded useful information for UK rheumatologists. Far 
from confirming concerns about higher toxicity with MTX, the results showed that more 
patients withdrew from IM gold treatment for any reason (p=0.014) or for toxicity 
(p=0.0026). 
The choice of clinical efficacy outcome assessment in the Gold /MTX trial is interesting, 
being the first in Glasgow to use a composite outcome measure – the Paulus 50% response 
criterion was a composite outcome measure using ESR, duration of early morning 
stiffness, patient global assessment of wellbeing and joint tenderness (Paulus et al. 1990). 
This was adapted for the use in the Gold/MTX trial, and a numerically greater number of 
patients made a good (50%) response to MTX than IM gold (27 vs 19), which approached 
statistical significance (Chi squared p=0.069). Clearly this raises the possibility of a type 2 
error, and that a caveat should be added to the conclusion reached at the time, which was 
that there were no differences in efficacy between IM gold and MTX. However, other 
comparative trials have reached broadly similar conclusions of similar efficacy, but more 
toxicity with IM gold (Lehman et al. 2005). 
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Low dose oral corticosteroid 
The use of corticosteroids in the treatment of RA has always been controversial (Myles 
1985). Very early reports of miraculous improvements in disease activity promised a new 
dawn in the therapy of this previously intractable disease. Early promise soon evaporated 
in the face of the development of serious corticosteroid toxicity, and the role of steroid 
therapy diminished. Despite early evidence that corticosteroids may be disease-modifying, 
most rheumatologists viewed corticosteroids as (ideally) short term symptomatic therapy. 
The prevalence of corticosteroid use varied quite dramatically: in Glasgow, it was used 
very sparingly as oral therapy, with a preference for intra-articular or intra-muscular 
triamcinolone used to treat acute flares of disease. Elsewhere in many parts of the world, 
low dose oral prednisolone was used in 40-60% of the RA population to control symptoms. 
However, the safety of this approach has been questioned in view of the association 
between corticosteroid use and adverse long term outcomes (Saag et al. 1994). Protagonists 
maintained that the association is not causal, but attributable to confounding by indication 
– namely that it is patients with severe disease that experience poor outcomes, and who 
also require corticosteroids. Antagonists to widespread corticosteroid use remain 
unconvinced, and concerned about infection, cardiovascular morbidity, osteoporosis and 
mortality. 
In 1995, the ARC Low Dose Corticosteroid Group published a well conducted, 
prospective, double blind randomised controlled trial comparing prednisolone 7.5mg daily 
with placebo in the treatment of early RA (Kirwan 1995). The study found that there was a 
significant reduction in the radiographic progression in patients treated with prednisolone. 
One limitation of the study rests in the fact that the use of DMARDs was left to the 
discretion of the attending rheumatologist. Given that these drugs are known to retard 
radiographic progression, an imbalance in their use between the study groups would have 
been a confounding factor. Whilst the study report documents that there were no 
significant differences in the use of DMARDs, only overall percentage use (not split for 
groups) of DMARDs was recorded. Perhaps more importantly, however, is the observation 
that only ~2/3 of patients were prescribed DMARDs at all. The precise figure is not 
deducible from the study report and may be lower than this if some patients received more 
than one DMARD during the study follow up. It is not known if the radiographic 
progression occurred predominantly in those patients not treated with DMARDs. 
The West Of Scotland Early RA Corticosteroid Therapy study (WOSERACT) was 
designed to test whether the findings of Kirwan et al could be replicated in a group of 
patients who were all being treated with the same DMARD therapy, namely, sulfasalazine. 
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The results did not replicate the findings of the earlier ARC Low Dose Corticosteroid 
Group study. It is possible that this was because the steroid was prescribed in combination 
with sulfasalazine in all patients. However, there are reasons to suspect that this might not 
be the case. Foremost among these are that there have been a number of subsequent trials 
that have confirmed the benefit of low dose corticosteroids in early RA, even when 
prescribed in combination with other DMARDs. A meta-analysis has confirmed that there 
is good evidence of disease-modification with corticosteroids, and the WOSERACT study 
appears to be an outlier (Saag et al. 1996). Why might this be? The first possibility is that 
assessors and/or participants could have become aware of treatment allocation due to 
unfortunate circumstances (the placebo tablet had to changed from pyridoxine to ascorbic 
acid following MHRA advice  to avoid long term pyridoxine use) which could have 
introduced bias. However, it is difficult to explain how unblinding of treatment allocation 
could influence radiographic progression, or the scoring of the radiographs by assessors 
who were undoubtedly still blinded to treatment group. 
An alternative possible explanation lies in the scoring of the radiographs: the radiographs 
were scored by two readers using slightly different techniques. One read the films in 
chronologically ordered pairs whereas the other read the films unaware of the order of the 
films. The scores from both readers showed no significant differences in radiographic 
progression between the groups, but there was a five-fold difference in the average scores 
recorded. Such differences are not explicable by the reported differences in methodology, 
and must reflect fundamental differences in what radiographic appearances were recorded 
as erosions or joint space narrowing (the two components that comprise the Total Sharp 
Score). However, despite the methodological differences, neither scorer found a significant 
difference in radiographic progression between groups. 
One finding that WOSERACT and the ARC Low Dose Corticosteroid Group studies both 
found was the lack of efficacy of low dose corticosteroids on acute phase response. This 
was somewhat surprising given the widespread use of corticosteroids to treat symptoms or 
flares of disease activity, but might suggest that the role of chronic low dose 
corticosteroids should be restricted to reducing radiographic progression. However, other 
recent reports have shown that within the context of a treat-to-target management strategy, 
the addition of low dose prednisolone not only reduces radiographic progression but also 
increases the rate of clinical remission (Bakker et al. 2012). Moreover, there are other 
appropriate uses of corticosteroid therapy – the COBRA (Boers et al. 1997) and BeSt 
(Goekoop-Ruiterman et al. 2005) studies show that high dose oral steroid can contribute to 
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rapid, early disease control, and the TICORA and TEAR trials used intra-articular and 
intra-muscular steroid as ‘bridge’ therapy in the early stages of DMARD therapy. 
Methotrexate and sulfasalazine combination therapy 
The acceptance of the need to treat patients with DMARD therapy gained very widespread 
acceptance over the 1980’s and 1990’s with the advent of high quality RCTs that 
demonstrated unequivocally that MTX, SSZ and leflunomide all have disease modifying 
properties (Scott et al. 2001, Strand et al. 1999). This enthusiasm for therapy was tempered 
by the observation that despite the use of DMARDs, the prognosis of RA remained poor. 
There were two main concerns: firstly, patients on DMARD monotherapy often continued 
to have persistent disease activity, and clinical remission was rare; secondly, a minority of 
patients continued on any DMARD long term as the result of a combination of poor 
efficacy and drug toxicity.(Maetzel et al. 2000, Felson, Anderson & Meenan 1990) The 
rise in popularity of MTX as the DMARD of first choice was largely the result of better 
long term continuation rates (compared to IM gold or sulfasalazine), rather than superior 
efficacy, but even MTX monotherapy fails to control most patients’ disease activity. 
The upshot was a growing interest in the use of combination DMARD therapy, to 
investigate whether such an approach would yield additional benefits at acceptable levels 
of toxicity. The results were mixed: some small studies suggested a modest increase in 
efficacy at the expense of a similarly modest rise in adverse effects (Bunch et al. 1984b); 
other studies failed to demonstrate any superiority of combination therapy (Porter, Capell 
& Hunter 1993). The two DMARDs most commonly prescribed at this stage were SSZ and 
MTX, with HCQ being used in patients will milder disease. Important evidence started to 
emerge in the 1990’s about the value of using combinations of these three DMARDs. Two 
studies showed that triple therapy resulted in better clinical outcomes and increased rates 
of remission (O'Dell et al. 1996, Mottonen et al. 1999). However, two well conducted 
RCTs failed to show any superiority of MTX/SSZ therapy over monotherapy with either 
drug  in early disease (Haagsma et al. 1994, Dougados et al. 1999). How were the results 
of these studies to be reconciled? Was dual therapy ineffective, but triple therapy effective? 
Questions were also being raised about the wisdom of using combination DMARD therapy 
in all patients when a proportion (approximately 30-40%) of patients respond well to 
monotherapy. 
The Methotrexate and Sulfasalazine Combination Therapy (MASCOT) trial was designed 
to explore these issues further. The trial design excluded patients with a good response (or 
early toxicity) from the study population, thereby enriching it for patients who might be 
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more likely to benefit from combination therapy. The results of the study supported the use 
of ‘step-up’ strategies of care, whereby patients with a sub-optimal response to their initial 
DMARD have a second DMARD added, rather than using sequential monotherapy. There 
are alternative combination strategies that can be pursued (parallel or step-down) but the 
results of MASCOT provided valuable confirmation of the step-up strategy, which has 
been endorsed by SIGN guidelines: 
A combination DMARD strategy, rather than sequential monotherapy, should be 
considered in patients with an inadequate response to initial DMARD therapy 
(Scottish Intercollegiate Guidelines Network 2011) 
Tight control of rheumatoid arthritis 
Evidence was emerging from other biological models that ‘tight control’ of disease may 
result in superior clinical outcomes. Foremost among these was Type 1 diabetes mellitus 
(DM) – the Diabetes Control and Complications Trial randomised patients to routine care 
or tight glycaemic control using multiple daily insulin injections. The results were a 
striking reduction in the development of micro-vascular complications such as retinopathy 
– for instance there was a 75% reduction in new episodes of retinopathy (primary 
prevention), and a 50% reduction in further deterioration of retinopathy (secondary 
prevention) (The Diabetes Control and Complications Trial Research Group 1993). Both 
RA and Type 1 DM are chronic auto-immune diseases in which severe complications arise 
insidiously over many years, resulting in significant morbidity and premature mortality. 
Following the publication of the results of the DCCT, a hypothesis emerged that similar 
improvements in outcome could be achieved in RA patients through ‘tight control’ of 
synovial inflammation. The Tight Control in RA (TICORA) study was designed to test this 
hypothesis. 
It is important to reflect that evidence from other biological models indicates that caution is 
wise before assuming that tight control will invariably or inevitably lead to superior 
outcomes. Firstly, the positive benefits of tight control may need to be weighed up against 
negative effects. For example, studies of primary and secondary prevention of 
cardiovascular events have clearly demonstrated that cholesterol lowering therapy (for 
instance with statins) results in improved cardiovascular outcomes. But emerging data 
shows that these improvements come at the cost of an increased incidence of Type 2 DM. 
Thus, the use of high dose atorvastatin (80mg daily) delivers a substantial reduction in 
cholesterol but for every three cardiovascular events that are saved, one new case of 
diabetes emerges (Sattar et al. 2010). 
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Secondly, not all tight control studies have demonstrated any effect. For instance, attempts 
to translate the tight control strategy of DCCT into the treatment strategies for the 
management of Type 2 DM have not delivered the expected reductions in macro-vascular 
complications (Hemmingsen et al. 2011). Thus, the TICORA study was needed to assess 
whether 1) tight control could be achieved 2) if so, whether this would lead to improved 
medium term outcomes 3) and if so, whether this benefit would be offset by significant 
costs, either financial (“would intensive management cost too much?”) or clinical (“would 
there be too many drug-related side effects?”).  
The strength of a strategy trial, is that it is not tied to the assessment of the efficacy of a 
single drug or drug combination. Rather, TICORA integrated the latest developments in 
clinical disease assessment (using DAS) with all drugs and drug combinations known to be 
efficacious into an all-embracing strategy that focussed on optimising care irrespective of 
which drug(s) were utilised.  
It is notable that the improvement in clinical outcome with intensive management was 
much more striking than the reduction in radiographic disease progression. Experience 
from trials of anti-TNF drugs has shown that, in established disease, radiographic damage 
in the hands and feet can be almost entirely halted (Maini et al. 1999). These results are 
seen despite the fact that the clinical response rates, while good, are not dramatically so. In 
TICORA, the reverse seemed to be true – the remission rates exceed those reported in trials 
of anti-TNF therapy, but the impressive stabilization of radiological damage is not seen. 
Why should this be so? Firstly, it must be remembered that the patient populations in these 
trials differ. The anti-TNF trials quoted above were conducted in patients with established 
RA, not in those with early disease. When anti-TNF therapy has been studied in early RA, 
continuing joint damage is seen, albeit at a reduced rate when compared with methotrexate 
therapy (Genovese et al. 2002). Secondly, it took several months to induce remission in 
most patients, and it is likely that radiological damage was progressing apace in this 
period. Thirdly, it was noted that there was a significant reduction in erosive damage, but 
no impact on joint space narrowing, and that the vast majority of the increased Sharp score 
consisted of deterioration in the joint space narrowing component of the score. It is 
possible that the pathological processes of cartilage loss and erosive damage are distinct, 
and that conventional DMARDs are more effective at ameliorating the latter. 
The finding that intensive outpatient management, often using multiple DMARDs, was 
associated with fewer drug related side effects is, on the face of it, surprising. However, 
similar findings were reported in the COBRA trial. It seems likely that the improved 
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general well-being of the patient contributes to a reduction in perceived (or actual) side 
effects. In TICORA, the frequent clinical review may also have facilitated additional 
patient education (perhaps reducing inappropriate drug cessation during intercurrent, but 
unrelated episodes), reassurance, and appropriate adjunctive therapy. 
The health economics assessment that was performed is reassuring. Before the trial, it was 
thought that there might be a trade off between improved clinical results and increased 
cost. In fact, the trial demonstrated no increase in overall costs, although it has to be noted 
that the confidence intervals for the estimates of cost were wide. Nonetheless, the trial 
suggests that the increased outpatient costs of intensive management are offset by reduced 
community healthcare costs, and, most importantly, reduced inpatient costs. This results in 
a cost-neutral intervention, with far superior clinical results, which suggested that this form 
of intensive intervention ought to find a place in routine clinical practice. 
It was important to establish whether the results of the trial were robust and reproducible. 
The trial was relatively small, and the impact of the intervention was greater than might 
have been predicted. Subsequently, however, other strategy trials have been published: 
1. CAMERA – this Dutch study used computerised algorithms to direct therapy in the 
intervention group, and found that this resulted in superior outcomes when 
compared to traditional physician directed care.(Verstappen et al. 2007) 
2. Fransen et al published the results of a study that randomised centres (rather than 
patients) to deliver ‘treat-to-target’ care or routine management, and again found 
that directing therapy according to the patients’ DAS delivers significant 
improvements of outcome.(Fransen et al. 2005) 
These three studies are the only ones that have sought to compare ‘treat-to-target’ or 
intensive management strategies with ‘routine’ care and their findings are consistent. Other 
studies (TEAR (Saunders et al. 2008), BeST (Goekoop-Ruiterman et al. 2005), SWEFOT 
(van Vollenhoven et al. 2009), CAMERA-II (Bakker et al. 2012)) have incorporated 
different elements of a ‘treat-to-target’ strategy but have focused on the comparison of the 
use of different drug regimens within that context. A systematic review has concluded that 
the evidence is ‘compelling’ and ‘unanimous’ that the use of a treat to target strategy of 
care is effective (Schoels et al. 2010). These conclusions are reflected in international 
consensus statements (Smolen et al. 2010) and clinical guidelines that recommend that 
patients are reviewed frequently, have their disease assessed using a composite measure of 
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disease activity, and have treatment escalated until the patient is in low disease activity or 
remission:  
Treatment should be aimed at reaching the target of remission or low disease 
activity as soon as possible, in every patient; as long as the treatment target has not 
been reached, treatment should be adjusted by frequent (every 1-3 months) and 
strict monitoring (Smolen et al. 2010) 
Triple therapy in Early RA 
The results of the TICORA study raised as many questions as it answered. Because the 
intensive management strategy comprised many different components, it wasn’t possible to 
tease out which are the most important. For instance, the improved outcomes might be the 
result of: frequent assessments with appropriate adjustment of therapy; or the liberal use of 
IA/IM steroid early in the disease course; the use of combination therapy; the close doctor-
patient relationship that developed; or any combination of these or other factors. At the end 
of the study (after 18 months of follow up), 56% of patients in the intensive group were 
receiving triple therapy with MTX/SSZ/HCQ. O’Dell et al had already published on the 
superiority of triple therapy over MTX monotherapy (O'Dell et al. 1996) and it was 
possible that this was a major contributor to the success of the TICORA strategy. If so, 
would the use of triple therapy from the outset lead to still greater response rates? Because 
of the complex nature of the treatment strategy, the ideal study design to address this issue 
was to compare two groups, both treated with an identical intensive treatment strategy, 
with a single difference: one group would start on triple therapy whilst the other group 
would be treated with a step-up regimen (as in TICORA). 
The results of the TEAR provided valuable information to complement the results of 
TICORA. Firstly, it was reassuring to have the effectiveness of intensive management 
confirmed in a second cohort of patients. At the end of 12 months ~40% of patients were in 
clinical remission; whilst this is less that the 65% remission rate reported in TICORA, this 
study was conducted over 18 months, and the remission rate at 12 months was very similar 
(unpublished data). Secondly, the results strongly suggested that treating all patients with 
newly diagnosed RA with triple therapy affords no advantages over employing a ‘step-up’ 
strategy whereby patients only move on to combination therapy if and when their disease is 
poorly controlled despite a three month trial of monotherapy. This has proved to be 
somewhat contentious, and requires further evaluation: 
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1. Several studies have shown that 30-40% of patients with newly diagnosed RA make a 
sustained good response to MTX monotherapy (van Vollenhoven et al. 2009, 
Goekoop-Ruiterman et al. 2005). Most patients and clinicians would prefer to avoid 
unnecessary combination therapy on the grounds of convenience, cost and safety. The 
TEAR study is encouraging evidence that patients do not suffer any ill effects from 
delaying combination therapy while a therapeutic trial of MTX monotherapy is 
undertaken within the context of an intensive management strategy. This rider is 
necessary because the frequent assessments (e.g. to address minor side effects, to 
ensure rapid escalation of therapy), use of bridging IM corticosteroid, and targeted use 
of IA steroid into swollen joints may be important in securing the efficacy of a step-up 
approach. 
2. There are discrepancies between UK national and European guidelines: the NICE 
Clinical Guidelines recommends that all patients with newly diagnosed, active RA 
should receive initial combination DMARD therapy, unless there are reasons not to 
(National Institute for Health and Clinical Excellence 2009). In contrast, EULAR 
guidelines indicate that initial monotherapy should be the norm unless there are poor 
prognostic indicators (although the evidence for using combination therapy in patients 
with adverse prognostic features (which are not defined) is lacking) (Smolen et al. 
2010). 
3. Some of the evidence cited for the superiority of initial combination therapy is drawn 
from trials comparing monotherapy with combination therapy, such as the FinRACo 
study (Mottonen et al. 1999) but outwith the context of a ‘treat-to-target’ or intensive 
strategy – i.e. patients on monotherapy were not given step-up therapy if they had 
persistent disease activity despite monotherapy. The BeSt study directly compared 
step-up therapy with initial combination therapy, and found a faster (but ultimately no 
greater) clinical response with reduced radiographic progression in the initial 
combination group (Goekoop-Ruiterman et al. 2005). However, there are some 
important features of the trial that should lead to caution before reaching a conclusion 
that initial combination therapy should be considered superior to monotherapy: firstly, 
the combination group received high dose oral corticosteroids (tapered to low dose 
over a few weeks) which is almost certainly the explanation for the rapidity of the 
response, and very likely to be the explanation for the reduced radiographic 
progression (because corticosteroid therapy has been demonstrated to reduce erosive 
change). Secondly, the step-up group did not receive intensive therapy in two regards: 
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the frequency of assessment was only quarterly (rather than monthly), and the use of 
intramuscular corticosteroid as ‘bridge therapy’ during the first three months of 
DMARD therapy was not allowed. 
In conclusion, the evidence suggests that a significant proportion of patients (up to 30-
40%) will respond well to MTX monotherapy. It’s not necessary to treat all patients with 
combination therapy from the outset, because delaying treatment to establish which 
patients require combination therapy leads to no long term ill effects. Rapidity of onset can 
be achieved by co-prescribing high dose oral corticosteroids or bridge IM steroid, and long 
term radiographic progression will be minimised by using low dose oral corticosteroids 
although this benefit must be offset against the potential deleterious effects of chronic 
steroid use. 
Some important issues that remain unresolved. Firstly, studies to date have mostly used 
DAS or DAS28 as the target for tight control. Other clinical/laboratory indices could be 
used, and the use of biomarkers has also been explored (van Tuyl et al. 2008). The use of 
musculoskeletal ultrasound as an adjunct to clinical examination is being studied, in view 
of its increased sensitivity to sub-clinical synovitis. Secondly, the decision about how low 
to aim is important: recent consensus statements have suggested that aiming for clinical 
remission is appropriate in most patients, although the evidence base is mainly drawn from 
studies like TICORA and TEAR in which low disease activity was the target (Smolen et al. 
2010). 
Conclusions  
The clinical trial programme in Glasgow has contributed significantly to our knowledge of 
how to treat newly diagnosed RA: the disease-modifying properties of DMARDs, the role 
of combination therapy, low dose oral corticosteroids and, especially, the advantages of 
employing an intensive management strategy have been elucidated. The early trials 
(SSZ/Aur, Gold/MTX and Gold/HCQ) were not, perhaps, as individually influential as 
TICORA but it is important to remember that at the time the debate about the risk/benefit 
of DMARDs continued to be brisk. These trials played a significant part in that debate by 
demonstrating that many DMARDs were both safe and effective. Nonetheless it is the later 
studies which have made a bigger international impact. The findings of the TICORA study 
have been endorsed in other studies, and national and European guidelines draw on the 
results directly in their recommendations for best practice. Early RA clinics have become 
increasingly widespread with the aim of delivering an intensive management strategy in all 
RA patients. Typically, after diagnosis, patients are reviewed monthly. At each visit, their 
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disease is formally assessed using the 28 joint disease activity score and management is 
guided by this. In most UK centres of excellence, patients are given combination therapy 
or are offered a step-up approach to drug therapy: starting with MTX, stepping up to triple 
therapy, and biologic therapy as required by the persistence of disease activity 
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Appendix 1 - Jadad Scores 
Study Randomisation Double Blind Withdrawals & 
Dropouts 
Total 
SSZ-Auranofin 0 0 1 1 
Gold-HCQ 2 2 1 5 
Gold-MTX 1 0 1 2 
WOSERACT 2 1 1 5 
MASCOT 2 2 1 5 
TICORA 2 0 1 3 
TEAR 2 0 1 3 
1 point is scored for each “Yes” or 0 points for each “No.”  
 
Q1. Was the study described as randomised (this includes the use of the words such as randomly, random, 
and randomisation)? 
Give an additional point if the method to generate the sequence of randomisation was described and it was 
appropriate (table of random numbers, computer generated, etc). Deduct a point if the method to generate 
the sequence of randomisation was described and it was inappropriate (patients were allocated alternately, 
according to date of birth, hospital number, etc). 
 
Q2. Was the study described as double blind? 
Give an additional point if the method of double-blinding was described and it was appropriate (identical 
placebo, active placebo, dummy, etc). Deduct a point if the method of blinding  was inappropriate (e.g., 
comparison of tablet vs, injection with no double dummy). 
 
Q3. Was there a description of withdrawals and dropouts? 
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Appendix 2 – Assessment of Risk of Bias 
SSZ/Aur trial 
Trial - SSZ vs Aur  Comments 
Random Sequence 
Generation 
Method of 
randomization not 
stated; not all 
patients randomised 
1. Patients(previously(treated(with(SSZ([n=25](or(Aur([n=4](were(assigned(to(other(drug( 
2. Patients(who(stopped(IM(gold(for(inefficacy(or(‘serious’(toxicity((proteinuria,(leucopaenia,(thrombocytopaenia)(were(assigned(to(receive(SSZ.(The(number(of(patients(previously(treated(with(IM(gold(and(assigned(to(SSZ(group(is(not(stated,(but(overall(40(patients(in(SSZ(group(and(26(in(the(Aur(group(had(previously(been(treated(with(IM(gold. 
Allocation 
Concealment 
Not stated Potential for randomisation bias 
Blinding of 
participants and 
personnel 
Participants – not 
blinded; personnel - 
not blinded 
Potential for bias 
Blinding of 
assessment 
Not blinded Potential for assessment bias 
Completeness of 
outcome data 
 No consort diagram provided; drop outs 
not included in the analysis - % analysed 
= 63% [SSZ] and 50% [Aur] 
Evidence of 
selective reporting 
None  
Other sources of 
bias 
 None identified 
Statistical analysis Power calculations 
– not reported 
Primary outcome – 
not stated 
Adjustment for 
multiple 
comparisons – none 
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Gold/HCQ trial 
Trial – Gold/HCQ  Comments 
Random Sequence 
Generation 
Yes Methodology not reported 
Allocation 
Concealment 
Yes Methodology not reported 
Blinding of 
participants and 
personnel 
Yes, double blind Yes; HCQ 400mg or matching placebo 
were prescribed to patients. neither 
participants nor personnel were aware of 
treatment allocation. Blinding of 
assessment 
Yes, double blind 
Completeness of 
outcome data 
‘Completer’ only 
analysis was 
performed 
Consort diagram provided complete 
information on the cohort of 440 patients 
who started on IM gold, and the reasons 
for not being randomised into the study 
after 6 months are provided. 
 
Drop outs – only patients completing 6 
months of therapy were included in the 
analyses, thereby excluding 50 patients 
(25 in each group). No intention to treat 
analysis was performed 
 
Evidence of 
selective reporting 
None  
Other sources of 
bias 
 None identified 
Statistical analysis Power calculations 
– not reported 
Primary outcome – 
not stated 
Adjustment for 
multiple 
comparisons – none 
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Gold/MTX trial 
Trial – IM gold vs 
MTX 
 Comments 
Random Sequence 
Generation 
Random number 
tables 
 
Allocation 
Concealment 
Inadequate There was inadequate concealment of the 
allocation process – treatments were 
allocated using random number tables to 
sequential study numbers that were then 
assigned to sequential patients. These 
were recorded in a trial master file that 
was not concealed; potentially the next 
treatment to be allocated could have been 
ascertained, could have influenced 
recruitment, and could have introduced 
allocation bias 
Blinding of 
participants and 
personnel 
Participants – not 
blinded; 
personnel - not 
blinded 
Potential for bias 
Blinding of 
assessment 
Not blinded Potential for bias - the published report 
almost certainly contains an error, stating 
that “patients, medical and metrology staff 
were unaware [emphasis added] of 
treatment allocation” but the abstract 
clearly states that this was an open label 
trial (confirmed by personal 
communication). 
 
Completeness of 
outcome data 
Complete Consort diagram – none, but the number 
of patients who declined to take part, and 
their stated reasons for so doing are 
recorded. 
Drop outs – patients who stopped their 
allocated therapy were included in some 
of the analyses using intention to treat. 
Within group analyses only used patients 
who remained on therapy without any 
‘last observation carried forward’ (LOCF) 
analyses. 
 
Evidence of 
selective reporting 
None  
Other sources of bias  None identified 
Statistical analysis Power 
calculations – not 
reported 
Primary outcome – 
not stated 
Adjustment for 
multiple 
comparisons – none 
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West of Scotland low dose corticosteroid trial 
Trial – WOSERACT  Comments 
Random Sequence 
Generation 
Randomisation 
software  
Randomisation used a minimisation 
technique to control for rheumatoid factor, 
age, gender, and the presence of erosions 
on baseline radiographs 
Allocation 
Concealment 
Good Performed  by remote study co-ordinator 
using randomisation software 
Blinding of 
participants and 
personnel 
Yes The study was double blind, but the 
placebo tablets did not match the 
prednisolone in appearance. Moreover, 
during the study, the appearance of the 
steroid tablets changed because of a 
change in supplier. In addition, the 
composition of the ‘placebo’ tablet 
changed mid-trial from pyridoxine to 
ascorbic acid as a result of an MHRA 
warning about the avoidance of long term 
pyridoxine. Together, these factors 
indicate a significant possibility that some 
patients or staff did not remain blinded to 
treatment allocation.  
Blinding of 
assessment 
Blinded The primary outcome measure for the trial 
was the change in the total Sharp Score 
and the readers of the radiographs were 
blinded to treatment allocation. 
Completeness of 
outcome data 
Complete Consort diagram – provided. 
Drop outs – the primary analysis was by 
intention to treat, and drop outs were 
accounted for. 
Evidence of 
selective reporting 
None  
Other sources of bias  None identified 
Statistical analysis Power 
calculations – yes 
Primary outcome – 
Change in Total 
Sharp Score 
Adjustment for 
multiple 
comparisons – N/A 
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MTX and SSZ combination therapy trial 
Trial – MASCOT  Comments 
Random Sequence 
Generation 
Randomisation 
software  
Randomisation used a minimisation 
technique to control for the presence of 
rheumatoid factor, erosions and disease 
duration. 
Allocation 
Concealment 
Good Performed  by remote study co-ordinator 
using randomisation software 
Blinding of 
participants and 
personnel 
Yes The study was double blind. Matching 
placebo tablets were provided by Wyeth 
(MTX placebo) and Pharmacia (SSZ 
placebo)  Blinding of 
assessment 
Blinded 
Completeness of 
outcome data 
Complete Consort diagram shown, including 
documentation of those patients who 
started Phase 1 on SSZ but were not 
randomised to the placebo controlled 
Phase 2. 
Drop outs – an intention to treat analysis 
was undertaken with the last observation 
carried forward. The number of patients 
completing Phase 2 in each group is 
recorded. 
Evidence of 
selective reporting 
None  
Other sources of bias  None identified 
Statistical analysis Power 
calculations – the 
study had >95% 
to detect a 
difference of one 
DAS unit at the 
2.5% significance 
level assuming a 
SD of 1.2 in 
change from 
baseline. 
Primary outcome – 
Mean reduction in 
DAS 
Adjustment for 
multiple 
comparisons – none 
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Tight Control of RA trial 
Trial – TICORA  Comments 
Random Sequence 
Generation 
Randomisation 
software  
 
Allocation 
Concealment 
Good Performed  by remote study co-ordinator 
using randomisation software 
Blinding of 
participants and 
personnel 
None Neither participants nor personnel were 
blinded to patient allocation – the nature 
of the strategy trial in which one group 
were followed up more frequently, and 
assessed more thoroughly renders this 
impossible. This introduces the potential 
for bias. 
Blinding of 
assessment 
Blinded Attempts were made to mitigate the risks 
of bias associated with the open study 
design: 1) the inclusion of objective 
outcome measures such as radiographic 
progression that might be less affected by 
any bias 2) the use of an assessor who was 
blinded to allocation for measuring all 
clinical outcomes  
Completeness of 
outcome data 
Complete Consort diagram shown, and intention to 
treat analyses were undertaken where 
appropriate. 
Evidence of 
selective reporting 
None  
Other sources of bias  None identified 
Statistical analysis Power 
calculations – yes 
Primary outcome – 
mean change in 
DAS 
Adjustment for 
multiple 
comparisons – none 
 
  50 
Triple Therapy in Early RA trial 
Trial – TEAR  Comments 
Random Sequence 
Generation 
Randomisation 
software  
 
Allocation 
Concealment 
Good Performed  by remote study co-ordinator 
using randomisation software 
Blinding of 
participants and 
personnel 
None Neither participants nor personnel were 
blinded to patient allocation. This 
introduces the potential for bias. 
Blinding of 
assessment 
Blinded Attempts were made to mitigate the risks 
of bias associated with the open study 
design: 1) the inclusion of objective 
outcome measures such as radiographic 
progression that might be less affected by 
any bias 2) the use of an assessor who was 
blinded to allocation for measuring all 
clinical outcomes  
Completeness of 
outcome data 
Complete Consort diagram shown, and intention to 
treat analyses were undertaken where 
appropriate. 
Evidence of 
selective reporting 
None  
Other sources of bias  None identified 
Statistical analysis Power 
calculations – yes 
Primary outcome – 
mean change in 
DAS28 
Adjustment for 
multiple 
comparisons – none 
 
